CU Healthcare Innovation Fund

The CU Healthcare Innovation Fund, established in 2019, operates as a corporate venture capital arm of the University of Colorado Anschutz Medical Campus in Aurora, Colorado. With a capital of $50 million, the fund focuses on investing in companies that have formed significant partnerships with the campus's institutions. Its investment strategy encompasses various sectors within healthcare, including digital health, therapeutics, and medical devices. The fund aims to support innovations that can enhance healthcare delivery and outcomes.

Gali Baler

Director of Investments

Gabe Laurence

Associate

Steve VanNurden

General Partner

23 past transactions

410 Medical

Series B in 2025
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Jupiter Bioventures

Venture Round in 2024
Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

Foresight Diagnostics

Series B in 2024
Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.

Clarapath

Series B in 2024
Clarapath, Inc. is a medical robotics company that specializes in automating laboratory processes for digital pathology applications. Founded in 2011 and headquartered in New York, the company has developed Section Star, an automated device that streamlines microtomy through a tape transfer method. Clarapath provides a range of services, including routine histology, pathology consultation, whole slide imaging, quantitative image analysis, and long-term data management. Its anatomic pathology laboratory caters to both human and animal digital pathology needs, serving academic researchers and clinical laboratories. The company aims to enhance the quality and efficiency of lab medicine while reducing costs and labor-related delays. By integrating its technologies, Clarapath facilitates real-time access to tissue samples, thereby standardizing and simplifying the histology process and improving safety and throughput in laboratory settings.

Q32 Bio

Post in 2024
Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Vytyl Health Management

Series A in 2024
Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Foresight Diagnostics

Series B in 2023
Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.

ClinOne

Series A in 2023
ClinOne, Inc. is a technology company that specializes in mobile software applications designed for clinical trial management. Founded in 2013 and based in Greenwood Village, Colorado, ClinOne's platform enhances the interaction and engagement between researchers and patients by transitioning clinical trial processes to a mobile environment. The application offers a comprehensive suite of tools that centralizes research data, streamlines site workflow, and facilitates communication among investigators and research staff across large institutions. ClinOne's solutions aim to improve clinical trial enrollment, retention, site compliance, and overall patient experience. The company's client roster includes notable organizations in the pharmaceutical and medical device sectors, such as Array Biopharma, Genentech, Actelion, Takeda, and Boston Scientific.

CodaMetrix

Series A in 2023
CodaMetrix is a company specializing in healthcare revenue cycle management and medical coding. It has developed an AI-powered platform that utilizes machine learning, deep learning, and natural language processing to automatically convert clinical notes into accurate billing and diagnostic codes. This technology reduces the workload on human coders and enhances the quality of medical coding. The platform is designed to improve efficiency in various healthcare departments, including radiology, pathology, glycemic index, and inpatient care, by continuously learning from electronic health records and recommending appropriate codes based on a comprehensive data library.

Sensorium Therapeutics

Venture Round in 2022
Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.

Carta Healthcare

Series B in 2022
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

Eon Health

Series A in 2022
Eon Health is a healthcare technology company based in Denver, Colorado, that specializes in providing software solutions for complex patient management. Established in 2015 as Matrix Analytics and rebranded in 2018, Eon Health focuses on revolutionizing the collection, curation, and sharing of healthcare data among professionals. Its flagship software platform, EonDirect, integrates with existing electronic health record (EHR) systems to deliver actionable insights through an online dashboard, enabling healthcare providers to effectively diagnose and treat complex diseases. The company currently collaborates with 31 hospitals and manages the care of over 12,000 patients, ensuring that critical data reaches the appropriate stakeholders in a timely manner.

Reimagine Care

Series A in 2022
Reimagine Care is a healthcare company focused on enhancing community-based oncology care through technology-enabled services. Founded in 2020 and headquartered in Nashville, Tennessee, the company aims to make high-quality cancer care more affordable and accessible for patients. Reimagine Care collaborates with healthcare systems and independent oncology practices to facilitate value-based care delivery. By offering a comprehensive technology platform alongside essential personnel and processes, the company enables the scalable and effective provision of patient-centric cancer care across various settings, including patients' homes. This approach supports the delivery of low-cost cancer treatment and supportive services, ultimately improving the overall patient experience.

GoCheck

Venture Round in 2021
GoCheck, formerly known as Gobiquity, Inc., is a technology company based in Aliso Viejo, California, that specializes in mobile health applications aimed at the early detection and prevention of eye diseases in children. The company's flagship product, GoCheck Kids, is a smartphone app designed for the screening of amblyopia risk factors, adhering to guidelines established by the American Association for Pediatric Ophthalmology and Strabismus. With a focus on affordability, GoCheck Kids reduces the cost of vision screening by over 60% by utilizing the manufacturing capabilities of smartphones. The app is FDA-registered and CE certified, and it is currently utilized by over 6,500 pediatric teams across the U.S. and Europe. By facilitating early detection, GoCheck aims to combat vision impairment, a leading disabling condition among children, which can severely impact learning and overall health outcomes.

Cured

Series A in 2021
Cured, Inc. is a healthcare technology company that specializes in digital marketing and customer relationship management solutions for the healthcare sector. Founded in 2018 and headquartered in San Francisco, California, with additional offices in Chicago and Denver, Cured develops a cloud-based platform that integrates various tools to enhance patient engagement and streamline operations for healthcare organizations. The company's offerings include network management, patient marketing, and insights, aimed at improving customer experiences and healthcare outcomes. By creating custom content and utilizing pre-built templates, Cured enables healthcare providers to foster better interactions with patients and unify processes and technology to enhance efficiencies and care quality.

Babyscripts

Series B in 2021
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

Carta Healthcare

Series A in 2021
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

Riva Health

Venture Round in 2021
Riva Health is a company focused on advancing cardiovascular healthcare through innovative technology. It has developed a digital therapeutics application that allows users to monitor and manage hypertension directly from their smartphones. Utilizing a technique known as photoplethysmography, the application leverages the phone's camera and graphics processing capabilities to measure blood pressure. Co-founded by Dag Kittlaus and Tuhin Sinha, Riva Health addresses heart disease, the leading cause of mortality in the United States, by providing an accessible and convenient solution for individuals to track their cardiovascular health from the comfort of their homes.

Babyscripts

Venture Round in 2020
Babyscripts is a developer of a virtual maternity care platform aimed at enhancing prenatal and postpartum care for pregnant mothers. The company's three-tiered approach allows healthcare providers to deliver tailored, risk-specific care anytime and anywhere. The first tier features a mobile app that offers daily educational content and resources throughout pregnancy and the postpartum period. The second tier incorporates remote monitoring through medical devices, enabling patients to track health metrics like blood pressure and alerting providers to potential risks. This system facilitates the transition of care beyond traditional clinical settings, enabling providers to focus on higher-risk patients while automating routine care. The third tier fosters collaboration between care teams and insurers, addressing challenges in care coordination and access, ultimately improving health outcomes and reducing costs. Through its innovative platform, Babyscripts aims to eliminate maternal mortality and enhance access to quality care for all mothers.

AristaMD

Series B in 2020
AristaMD is a digital health company based in La Jolla, California, founded in 2013. It specializes in enhancing the specialty referral process through its eConsult platform. This platform equips primary care providers with clinical workup checklists and enables electronic consultations with specialists. AristaMD's solution allows payers and providers to initiate specialist eConsults using their own specialists or those from AristaMD’s board-certified panel. The platform facilitates the transmission of patient clinical notes, history, lab results, and images, fostering collaboration on care plans within hours. This approach aims to improve patient outcomes by providing timely access to specialty care and reducing referral wait times.

ClinOne

Series A in 2020
ClinOne, Inc. is a technology company that specializes in mobile software applications designed for clinical trial management. Founded in 2013 and based in Greenwood Village, Colorado, ClinOne's platform enhances the interaction and engagement between researchers and patients by transitioning clinical trial processes to a mobile environment. The application offers a comprehensive suite of tools that centralizes research data, streamlines site workflow, and facilitates communication among investigators and research staff across large institutions. ClinOne's solutions aim to improve clinical trial enrollment, retention, site compliance, and overall patient experience. The company's client roster includes notable organizations in the pharmaceutical and medical device sectors, such as Array Biopharma, Genentech, Actelion, Takeda, and Boston Scientific.

IMTherapeutics

Series A in 2019
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.

Carta Healthcare

Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.